All In Biotech

NDA 011153 · Pfizer

Medrol

Methylprednisolone · Oral · Corticosteroid

Novel

Last checked: Nov 20, 2026Latest source record: Nov 4, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1957

Oct 24, 1957

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,078

579 Phase 3, 236 recruiting

FAERS reports

124,181

110,690 serious, 19,405 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 31, 2026.

INDICATIONS AND USAGE Methylprednisolone tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 24, 1957 Original approval · Type 1 - New Molecular Entity
6 products under this application
  • MEDROL · METHYLPREDNISOLONE 24MG · TABLET, ORAL · Discontinued
  • MEDROL · METHYLPREDNISOLONE 16MG · TABLET, ORAL · Prescription · TE AB
  • MEDROL · METHYLPREDNISOLONE 4MG · TABLET, ORAL · Prescription · TE AB
  • MEDROL · METHYLPREDNISOLONE 32MG · TABLET, ORAL · Prescription · TE AB
  • MEDROL · METHYLPREDNISOLONE 8MG · TABLET, ORAL · Prescription · TE AB
  • MEDROL · METHYLPREDNISOLONE 2MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Methylprednisolone" as an intervention, any sponsor and status, largest first.

All 2,078 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use18,660
  • drug ineffective14,392
  • fatigue6,387
  • nausea6,032
  • pain5,898
  • headache5,777
  • pneumonia5,729
  • pyrexia5,721
  • dyspnoea5,449
  • arthralgia5,351
  • diarrhoea5,294
  • condition aggravated5,023

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004825
2005878
2006944
2007826
20081,124
20091,138
20101,855
20112,377
20122,922
20132,671
20143,195
20153,989
20164,632
20175,753
20188,014
20199,407
202012,161
202111,536
202211,383
202310,448
202410,700
202510,662
20266,733

Recalls

1 FDA enforcement reports for this application.

  • Jan 15, 2026 · Class II · Ongoing

    Labeling: Not Elsewhere Classified. Incorrect orientation of the blister foil applied to the blister cavities, which results in incorrect dosing information when following the directions on the foil.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Medrol (Methylprednisolone)

2024 spending

$10K

Beneficiaries

737

898 claims

Per beneficiary

$13

$0.34 per unit

View as table
YearSpending
2020$181,016
2021$53,242
2022$13,626
2023$10,821
2024$9,693

Part B: Medrol* (MethylprednIsolone*) · HCPCS J7509

2024 spending

$5K

Beneficiaries

99

663 claims

Per beneficiary

$50

2024 ASP limit $0.24 per unit

View as table
YearSpending
2020$9,904
2021$8,711
2022$7,088
2023$5,364
2024$4,907

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,726 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.